A股異動 | 新冠檢測概念逆勢走強,檢測試劑價格暴漲
格隆匯1月10日丨新冠檢測概念逆勢走強,安旭生物連續三個20CM漲停,熱景生物、奧泰生物漲幅在10%以上。由於海外疫情嚴峻,全球新冠病毒檢測試劑盒需求激增。在美國,通常兩劑快篩的試劑盒售價14~24美元,如今因貨源短缺,在部分市場上該價格已經翻倍,達到75美元,甚至還有標價80美元。BCC Research調研報吿預計,2020年全球新冠檢測市場高達603億美元,預計2021年844億美元,2027年將增至1951億美元,年均複合增長率達到15%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.